# Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome

> **NCT01068795** · NA · COMPLETED · sponsor: **HaEmek Medical Center, Israel** · enrollment: 144 (actual)

## Conditions studied

- Fetal Demise
- Fetal Growth Restriction
- Preeclampsia
- Abruptio Placentae
- Thromboembolism

## Interventions

- **DRUG:** enoxaparin

## Key facts

- **NCT ID:** NCT01068795
- **Lead sponsor:** HaEmek Medical Center, Israel
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2015-01
- **Final completion:** 2015-08
- **Target enrollment:** 144 (ACTUAL)
- **Last updated:** 2016-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01068795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01068795, "Dose Adjusting Enoxaparin Thromboprophylaxis Dosage According to Anti-factor Xa Plasma Levels Improve Pregnancy Outcome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01068795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*